Loading...

Theradiag SA

ALTER.PA•EURONEXT
Healthcare
Medical - Devices
€1.26
€-0.06(-4.91%)

Theradiag SA (ALTER.PA) Stock Overview

Explore Theradiag SA’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.9/100

Key Financials

Market Cap17.3M
P/E Ratio-33.61
EPS (TTM)$0.03
ROE-0.06%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$1.77

ALTER.PA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Theradiag SA (ALTER.PA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $1.77.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -33.61 and a market capitalization of 17.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for ALTER.PAStats details for ALTER.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ALTER.PAAnalyst Recommendations details for ALTER.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Theradiag SA develops, manufactures, and markets in-vitro diagnostic products. It offers autoimmunity reagents; IMMUNO-TROL, a multi-parametric quality control tool; various instruments for autoimmunity and infectious diseases testing; SQA-V system, a semen analyzer; and V-Sperm for loading results, pictures, and videos of the samples into the computer. The company also provides instrumentation, including Theralis that integrates multiplex FIDIS immunofluorescence and ELISA; Theralis µ, a solution for medium sized laboratories; and FIDIS platform used in laboratory for analysis. In addition, it offers therapeutic drug monitoring services for treatment of chronic inflammatory diseases; and LISA tracker, a tool for monitoring of biotherapies, as well as Elisa and rapid tests for SARS-CoV 2 serology. The company was founded in 1986 and is based in Marne La Vallee, France.

CEO

Simon Daviere

Employees

60

Headquarters

14 rue Ambroise Croizat, Marne-la-Vallée

Founded

2012

Frequently Asked Questions

;